22 March 2022 - Since the start of 2022, China’s National Medicinal Products Agency has made strides to increase greater access to biosimilar products for various rheumatic conditions, including 3 biosimilar approvals and 1 biosimilar receiving an expanded indication.
China has been an emerging market for quite some time, having its first biosimilar approval in February 2019, which was a rituximab biosimilar (Hanlikon) developed by Henlius Fuhong Henlius referencing Rituxan.